Rational design of lipid-based nanoparticles for targeted anticancer therapies.

Area of Science:

• Nanomedicine
• Drug Delivery
• Oncology

Background:

• Targeted anticancer therapies face pharmacokinetic and biological barriers like poor bioavailability and tumor penetration.
• First-generation lipid-based nanoparticles (LBNPs) utilized the EPR effect, but tumor heterogeneity necessitates improved targeting strategies.

Purpose of the Study:

• To provide an integrative analysis of rational LBNP design for targeted anticancer therapies.
• To correlate LBNP structural complexities with specific therapeutic modalities and biological barriers.

Main Methods:

• Systematic exploration of LBNP design rules based on therapeutic modality.
• Discussion of nanocarrier optimization (liposomes, SLNs, NLCs) via lipid composition, surface functionalization, and ionizable lipids.
• Evaluation of administration routes and formulation methods (emulsification, microfluidics, supercritical fluid technology).

Main Results:

• Distinct LBNP structural designs are dictated by therapeutic modalities and biological barriers.
• Customized lipid compositions, surface functionalization, and ionizable lipids enhance nanocarrier performance.
• Advanced formulation platforms offer advantages over traditional methods.

Conclusions:

• Transitioning nanomedicines to clinical use is hindered by manufacturing and regulatory bottlenecks, not preclinical efficacy.
• Addressing chemistry, manufacturing, and controls (CMC) challenges and ensuring scalability are critical.
• Harmonized regulatory frameworks are essential for the future clinical success of targeted nanomedicines.